CTI BioPharma (NASDAQ: CTIC) reported Q1 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $2.73 million versus the consensus estimate of $9.84 million.

For earnings history and earnings-related data on CTI BioPharma (CTIC) click here.